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Objective: Monocytes are motile cells which sense inﬂammatory stimuli and subsequently migrate to
sites of inﬂammation. Key players in host defense, monocytes have nevertheless been implicated as
requisite mediators of several chronic inﬂammatory diseases. Inhibition of monocyte chemotaxis is
therefore an attractive anti-inﬂammatory strategy. Oxidized phospholipids (OxPL) are native regulators
of inﬂammation, yet their direct effect on monocyte chemotaxis is poorly deﬁned. In this study, we
investigated the direct effect of natural and synthetic phospholipids on monocyte chemotaxis.
Methods: Exploring various phospholipids using in vitro chemotaxis assays, we found that the natural
phospholipid 1-palmitoyl-2-glutaryl phosphatidylcholine (PGPC) can decrease monocyte chemotaxis by
50%, while other tested OxPL had no effect. We generated a library of synthetic OxPL designated lec-
inoxoids, which was screened for anti-inﬂammatory properties.
Results and conclusions: VB-201, a small-molecule lecinoxoid, exhibited up to 90% inhibition of monocyte
chemotaxis in vitro. Molecular analysis revealed that the effect of VB-201 was not restricted to a speciﬁc
chemotactic ligand or receptor, and resulted from inhibition of signaling pathways required for monocyte
chemotaxis. Interestingly, VB-201 did not inhibit monocyte adhesion or phagocytosis and had no effect
on chemotaxis of CD4þ T-cells or neutrophils. In vivo, oral treatment with VB-201 reduced monocyte
migration in a peritonitis model and inhibited atheroma development in ApoE/mice, without affecting
cholesterol or triglyceride levels. Our ﬁndings highlight a novel role played by native and synthetic
phospholipids in regulation of monocyte chemotaxis. The data strengthen the involvement of phos-
pholipids as key signaling molecules in inﬂammatory settings and demonstrate their potential thera-
peutic applicability.
 2013 The authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Monocytes are key players in the immune system, with critical
roles in innate and adaptive immunity, immune surveillance and
particle scavenging [1,2]. Circulating monocytes can sensecence-activated cell sorting;
ipoprotein; MCP-1, monocyte
lipid; PAPC, 1-palmitoyl-2-
, oxidized PAPC; PGPC, 1-
ve oxygen species.
: þ972 3 6346449.
Ltd .Open access under CC BY-NC-NDinﬂammatory stimuli and quickly migrate through the vascular or
lymphatic endothelium to the periphery [2]. While playing a
necessary role in host defense, monocytes were nonetheless
identiﬁed as critical mediators of several inﬂammatory disorders,
including atherosclerosis, rheumatoid arthritis and multiple scle-
rosis [3e5]. Suppressing the accumulation of unwantedmonocytes/
macrophages in a chronically inﬂamed tissue has a therapeutic
potential, and migration inhibitors have accordingly demonstrated
beneﬁcial therapeutic results in animal models and clinical trials.
Extensive research has shown that chemokine receptors and
adhesion molecules play a key role in regulation of leukocyte
trafﬁcking (reviewed in Refs. [1,6]). A complex array of chemokine
receptors, G-protein coupled receptors (GPCRs) that are differen-
tially expressed on leukocyte lineages and subsets, regulates which
cell types would migrate and to which tissue, under different
conditions. Chemokines are secreted proteins that regulate license .
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the case of inﬂammatory monocytes, diapedesis and intravasation
are processes dependent on CeC motif receptor 2 (CCR2) signaling,
in response to activation by the CCL2 (also known as MCP-1) and
CCL7 (MCP-3).
Phospholipids are much more than structural components of
cellular membranes. Subjected to enzymatic and chemical modi-
ﬁcations, modiﬁed phospholipid species serve as key signaling
molecules and secondary messengers affecting multiple biological
systems, including innate and adaptive immune responses [8].
Oxidized phospholipids (OxPLs) are abundantly found at sites of
inﬂammation and are involved in modulation of the immune
response. Most studies have attributed a pro-inﬂammatory role to
OxPLs, as in the case of low density lipoprotein (LDL) oxidation
products which accumulate in vessel walls and promote athero-
sclerosis [9,10]. Minimally-modiﬁed and oxidized LDL components
bind to scavenger, nuclear, Toll-like, and G-protein coupled re-
ceptors on endothelial, smooth muscle cells and macrophages,
subsequently inducing secretion of multiple chemokines and
facilitating chemotaxis of pro-inﬂammatory leukocytes [9e12].
However, multiple different OxPL species can be found in vivo and
while some promote inﬂammation, other OxPLs exhibit anti-
inﬂammatory effects [13]. Several groups have demonstrated
OxPL-mediated inhibition of Toll-like receptor signaling, produc-
tion of anti-inﬂammatory compounds and protection of endothelial
cell barrier [14e16], properties which may indirectly reduce
leukocyte recruitment.
Additional phospholipid species were shown to affect cell
migration. The lipid mediators, lysophosphatidic acid (LPA) and
sphingosine-1-phosphate (S1P) which regulate a complex array of
GPCRs, were reported to either enhance or reduce chemotaxis of
different cell types [17]. Taken together, these studies point to an
important role played by physiological phospholipids in regulation
of immune cell chemotaxis. Yet, to the best of our knowledge, a
direct and clear in vivo inhibition of monocyte migration by a
phospholipid molecule has not been reported thus far.
Atherosclerosis is a complex disorder involving lipid retention,
inﬂammation, oxidative stress and endothelial dysfunction.
Monocytes play a key role in initiation and progression of athero-
sclerosis. Evidence to their critical role can be found in studies of
the M-CSF mutation in mice, which abolished aortic atherogenesis
in the ApoE knockout (KO) model in spite of high lipid levels [18,19].
Conditions of atherosclerosis induce a rapid inﬂux of inﬂammatory
monocytes to the vessel wall which is followed by differentiation of
the monocytes to inﬂammatory macrophages and DCs. Migrating
as well as resident macrophages and DCs, along with inﬁltrating T-
cells, undergo phenotypic changes and modulate the inﬂammatory
milieu within the arterial wall [20].
VB-201 is a novel, orally available, non-oxidative synthetic
phospholipid analog of the lecinoxoid (lecin for lecithin, i.e. a
phospholipid and oxoid for oxidized) family. Structurally related to
the native compound 1-palmitoyl-2-glutaryl phosphatidylcholine
(PGPC), VB-201 was engineered towards enhanced in vivo stability,
through chemical modiﬁcations at sn-1 and sn-2 positions of the
glycerol backbone. Recently, we demonstrated that VB-201 has a
profound effect on the onset and severity of experimental auto-
immune encephalomyelitis (EAE) mouse model of multiple scle-
rosis, reducing the number of immune cells inﬁltrating the spinal
cord and restraining the Th1 response of treated animals [21].
Furthermore, VB-201 was found to attenuate inﬂammation in
additional experimental immune-mediated models (unpublished
data) and after successful completion of phase I, is currently tested
in phase II clinical trials. Yet, the mechanism of action by which VB-
201 (and the lecinoxoids in general) reduces inﬂammation was
unknown. Here we report ﬁndings that unravel a cellular andmolecular anti-inﬂammatory role for lecinoxoids in general and
VB-201 in particular.
2. Materials and methods
2.1. Materials
VB-201 and VB-207 (an inactive derivative of VB-201, used as a
negative control) are proprietary molecules synthesized by VBL
Therapeutics. Chemoattractants were purchased from Peprotech.
GW5074 was purchased from Sigma. Rapamycin and Wortmannin
were from EMD-Millipore. 1-Palmitoyl-2-arachidonoyl-sn-glycero-
3-phosphocholine (PAPC) and 1-palmitoyl-2-glutaryl phosphati-
dylcholine (PGPC) were purchased from Avanti Polar Lipids. PAPC
was oxidized for 24 or 72 h prior to use, as indicated. THP-1 cells
were purchased from ATCC. RPMI-1640 medium and fetal bovine
sera were from Biological Industries Ltd., Israel. FicollePaque plus
was from GE Healthcare. HUVEC were freshly isolated from blood
cords of donors and grown in EGM-2 medium (Lonza). Thio-
glycollate solution was purchased from Hy-Labs, Israel.
2.2. Animals
Apolipoprotein E knockout (ApoE KO) mice were bred in-house
at the Bert W. Strassburger Lipid Center Sheba Medical Center,
Tel-Hashomer, Israel. C57B6/J WT mice were purchased from Har-
lan (Rehovot, Israel). All mice were fed a chow diet. For in vivo
examination of monocyte migration, C57B6/J WT mice (age 9e12
weeks) were orally administered with VB-201 at dose of 0.04, 0.4 or
4 mg/kg once daily for 8 days. On day 5, thioglycollate was injected
to the peritoneal cavity of the mice to induce monocyte migration.
Three days later mice were sacriﬁced and cells were collected from
the peritoneum and counted by hemocytometer.
For atherosclerosis study, 9e11-week old male ApoE KO mice
were administered with VB-201 (1.5 mg/kg) or PBS by oral gavage.
Dosing was performed once a day, for 8 weeks (n ¼ 11e12/group).
Atherosclerotic lesions were quantiﬁed by calculating the lesion
size in the aortic sinus as previously described [1]. All animal ex-
periments were approved by the Institutional Animal Care and Use
Committee of the Sheba Medical Center, Ramat Gan, Israel.
2.3. Human specimens
Blood samples and umbilical cords were obtained from healthy
donors. The study design was approved by the ethics committee of
Sheba Medical Center, and all subjects provided written informed
consent.
2.4. Cell viability assays
Following incubation with the indicated doses of VB-201 for
16 h, cell viability was analyzed using CellTiter MTS assay (Prom-
ega) according to the manufacturer’s protocol.
2.5. Western blot analysis
For Western blot analyses, cells were washed twice with PBS,
harvested in denaturing lysis buffer containing protease & phos-
phatase inhibitor cocktails (Pierce) and boiled for 5 min. Lysates
were resolved on Any-KD Criterion gels (Biorad) and transferred to
nitrocellulose membranes. For immune-blotting, phospho-AKT
(Ser473)(D9E), AKT, p-MEK1/2 (Ser217/221) (41G9) and p-
p38(Thr180/Tyr 182)(D3F9) were purchased from Cell Signaling
Technology; ERK1/2 and p-ERK1/2(diphosphorylated) antibodies
were from Sigma; p38 (A-12) and MEK1 (H-8) antibodies were
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bodies were from Jackson Immunoresearch. Signal was developed
using ECL kit (Pierce).
2.6. Immunohistochemistry
Immunostaining was performed on frozen sections which were
ﬁxed with cold acetone and blocked with 4% normal rabbit serum/
PBS (Vector Lab). Following incubation with rat anti-mouse CD68
(Serotec NCA1957; 1:250) and anti-rat biotinylated antibody
(Vector Lab AB-4001; 1:200), signal was developed using Vectas-
tain ABC-alkaline phosphatase kit and Vector Red Substrate (Vector
Lab). Mayer’s hematoxylin was used for counterstaining.
2.7. In vitro cell migration assay
Human monocytes (CD14þ cells), CD4þ T-cells and neutrophils
were isolated fromwhole blood of healthy donors. Following PBMCs
separation fromwhole blood using FicollePaque and leucosep tubes
(Greiner Bio-One), CD14þ/CD4þ/CD66þ cells were separated using
speciﬁc anti-CD14/anti-CD4/anti-CD66abce micro-beads, respec-
tively (Miltenyi Biotec). Purity of the isolated populations was vali-
dated using speciﬁc antibodies by FACS analysis. Isolated cells were
pre-incubated for 30 min with solvent (0.005% ethanol/PBS) or VB-
201 as indicated. For chemotaxis of monocytes, RANTES (100 ng/
ml), MIP-1a (50 ng/ml) or MCP-1 (50 ng/ml) were dissolved in 0.5%
FBS/RPMI-1640 and placed at the lower chamber of QCM 24-well
migration assay plate (Corning-Costar; 5 mm pores). For chemo-
attraction of CD4þ cells, 0.5% FBS/RPMI-1640 solution containing
RANTES (100 ng/ml) and SDF-1a (50 ng/ml) was used, using the
same plate setting. Chemo-attraction of neutrophils was done using
2% FBS/RPMI-1640 solution containing LPS (100 ng/ml), or 10% FBS/
RPMI-1640 supplementedwithMCP-3 (100 ng/ml).Migration assay
was conducted by seeding 300,000 treated cells in the upper
chamber, followed by incubation of 3e4 h. Subsequently, the num-
ber of cells which migrated to the medium in the lower compart-
ment was determined by FACS. For analysis of chemotaxis in the
THP-1 line, cells were suspended in 0.5% FBS/RPMI-1640 and pre-
incubated for 1 h with the PI3K inhibitor Wortmannin (1 mmol/l),
the mTOR inhibitor Rapamycin (1.1 mmol/l) or the RAF inhibitor
GW5074 (1 mmol/l), followedbyaddition of solvent (0.005% ethanol/
PBS) or VB-201 (5 mg/ml) for 30min. Assayswere performed for 3 h,
using 2% FBS/RPMI-1640 supplemented with RANTES (100 ng/ml)
and MCP-1 (100 ng/ml) for cell attraction.
2.8. Quantiﬁcation of chemokine receptor expression level
HumanCD14þmonocyteswere incubated for3.5h in2%FCS/RPMI
medium with solvent or VB-201. Cells were then washed, resus-
pended in PBS containing 2% FCS and 0.02% sodium azide (FACS
buffer) and stained for 30min at 4 Cwith anti-CCR1-Alexa Fluor 647
(BD Biosciences), anti-CCR5-PE, anti-CXCR1-PE, anti-CXCR2-Alexa
Fluor 647, anti-CCR7-PE and anti-CCR2-PerCP-Cy5.5 (all from
BioLegend). Cells were washed, resuspended in FACS buffer and
analyzed on a FACS-Calibur device.
2.9. GPCR activation assay
FLIPR assays were conducted by Millipore GPCR Proﬁler Service
to screen VB-201 and VB-207 (inactive derivative of VB-201, as a
negative control) for dose-dependent agonist and antagonist activ-
ities on the GPCRs listed. Sample compounds were plated in serial
dilutions in assay buffer (1 HBSS with 20 mmol/l HEPES and
2.5 mmol/l Probenecid), with a top concentration of 10 mmol/l.
Agonist percentage activation determinations were obtained byassaying the test compounds and referencing theEmaxcontrol for the
GPCRs proﬁled. Antagonist percentage inhibition determinations
were obtained by assaying the test compounds and referencing the
control EC80 wells for the GPCRs proﬁled.
2.10. Isolation and staining of mouse peritoneal cells
Three days after intraperitoneal injection of C57B6/J mice (8e10
weeks) with 1.5 ml of thioglycollate solution (Hy-labs, Israel), mice
were euthanized by CO2 and cells were collected from the perito-
neal cavity by 3e4 washes with ice-cold PBS. Following removal of
erythrocytes with RBC lysis buffer (Biological Industries, Israel),
cells were resuspended in RPMI medium and counted by light
microscopy. For characterization of the cell population, cells were
stained with anti-GR-1 (neutrophils marker) conjugated to PE and
anti-F4/80 (macrophages marker) conjugated to PerCP-Cy5.5 (both
from eBioscience). Fluorescence intensity was quantiﬁed by FACS.
2.11. Statistical analysis
Mean  standard deviation/standard error was calculated using
Excel or Sigma-Stat software, and the statistical signiﬁcance was
calculated by two-tailed Student t-test. To compare between
experimental groups one way ANOVA or t-test was used. p value of
<0.05 was considered as statistically signiﬁcant.
3. Experimental results
3.1. PGPC and VB-201 inhibit human monocyte chemotaxis in vitro
Investigating potential anti-inﬂammatory roles of OxPLs, we
were interested in testingpossible effects of native phospholipids on
monocyte chemotaxis directly. OxPLs were previously reported to
increase monocyte adhesion to endothelial cells [10,22], however,
these effects resulted from activation of the endothelial cells which
was followed by cytokine secretion and enhanced expression of
adhesion molecules, while the monocytes themselves were not
treatedor studied.We therefore chose to avoid the presence of other
cell types and performed in vitromonocyte chemotaxis assays using
isolated human monocytes and recombinant chemoattractants.
For this purpose, monocytes from healthy donors were pre-
incubated for 30 min with either solvent (0.005% ethanol/PBS),
phosphatidylcholine (PC; 5 mg/ml), partially oxidized PAPC (24 h
oxidation; 40 mg/ml) or PGPC (5 mg/ml), and allowed to migrate
towards recombinant human MCP-1 (CCL2; ligand for CCR2) and
RANTES (CCL5; ligand for CCR1, CCR3, CCR5, US28) as attractants
(50 ng/ml each). Interestingly, whereas PC and partially oxidized
PAPC did not reduce the number of migrating cells, treatment with
pure PGPC, an oxidized product of PAPC, signiﬁcantly attenuated
monocyte chemotaxis byw50% (Fig.1A). This unexpected result led
us to screen through a library of Lecinoxoids for additional com-
pounds that may inhibit monocyte chemotaxis. The screen yielded
VB-201, a synthetic saturated phospholipid which is structurally
related to PGPC (Supplementary Fig. 1 A,B), that demonstrated
profound inhibition of monocyte chemotaxis (Fig. 1A). Increased
potency of VB-201 over PGPC was further validated using dose-
escalating chemotaxis assays (Supplementary Fig. 1C).
We have repeated the assays, employingMCP-1, RANTES orMIP-
1a (CCL3; ligand for CCR1,CCR5) as chemoattractants and found
that compared to the solvent control, VB-201 signiﬁcantly and
profoundly reduced monocyte migration by approximately 80% for
MCP-1, 72% for RANTES and 68% for MIP-1a (Fig. 1B). VB-201 also
inhibited in a dose-dependent fashion monocyte migration to-
wards growth medium taken from a culture of human umbilical
Fig. 1. VB-201 inhibits chemotaxis of human monocyte in vitro. (A) Human monocytes (CD14þ) isolated from blood of healthy donors were pre-treated for 30 min with either
solvent, phosphatidylcholine (PC; 5 mg/ml), oxidized PAPC (40 mg/ml, 24 h oxidation), PGPC (5 mg/ml) or VB-201 (5 mg/ml), and then subjected to transwell chemotaxis assay, using
MCP-1 and RANTES mix (50 ng/ml each) for attraction. The number of cells migrating to the lower compartment was determined by FACS, and normalized to the solvent control.
Data are mean  SD from a representative experiment performed in triplicates. (B) CD14þ cells were treated with solvent or VB-201 (5 mg/ml) prior to chemotaxis assay using MCP-1
(50 ng/ml), MIP-1a (50 ng/ml) or RANTES (100 ng/ml) as attractants. Data are mean  SD (n ¼ 3, in triplicates). (C) Effect of escalating doses of VB-201 or oxidized-PAPC (Ox-PAPC)
on CD14þ migration towards HUVEC supernatant. Data represent mean  SD (n ¼ 3, in triplicates). (D) MTS assay in human monocytes subjected to escalating doses of VB-201 for
16 h, demonstrates that VB-201-inhibited chemotaxis is not due to reduced cell viability (mean  SD; n ¼ 7 in quadruplicates). Statistically signiﬁcant (p < 0.05) differences relative
to solvent are marked with asterisk.
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seen with fully oxidized PAPC for any of the doses tested (Fig. 1C).
To exclude the possibility that inhibition of monocyte migration
by VB-201 results from cell death, monocytes were treated with
escalating doses of VB-201 for 16 h, after which cell viability was
determined byMTS assay. As shown in Fig.1D, VB-201 had no effect
on monocyte viability at doses of 1e10 mg/ml. Along that line, VB-
201 also inhibited chemotaxis of monocytic THP-1 cells without
affecting their viability (Supplementary Fig. 2).
To ensure that VB-201 is not an oxidative molecule which may
induce ROS and damage cells, human monocytes were incubated
overnight with PBS, VB-201 (10 mg/ml), PGPC (10 mg/ml) or the
positive control OxPAPC (100 mg/ml; oxidized for 24 h) and ROS
formation was tested as described in the Methods section. As ex-
pected, OxPAPC signiﬁcantly elevated ROS in human monocytes
relative to PBS-treated cells. However, VB-201 and PGPC had no
effect on ROS formation in primary monocytes (Supplementary
Fig. 3). Similarly, VB-201 did not affect monocyte secretion of IL-
6, IL-8 or MCP-1 (Supplementary Fig. 4, and data not shown), in
contrast to the reported stimulation of inﬂammatory cytokine
release by certain OxPL [23].
Collectively, these ﬁndings indicate that some phospholipid mol-
ecules, such as PGPC and VB-201, can inhibit monocyte chemotaxis
in vitro. Notably, this effect is compound-speciﬁc and does not result
from a general phospholipid-related phenomenon (a class effect).3.2. Monocyte phagocytosis and adhesive properties are not
affected by VB-201
Given the inhibition ofmonocyte chemotaxis by VB-201, wewere
interested to test whether VB-201 affects additional monocyticfunctions. To this end, phagocytosis assay was performed on whole
blood from healthy donors, in presence or absence of VB-201. Inter-
estingly, VB-201 doses of 5 or 10 mg/ml that were effective in inhibi-
tion of monocyte migration did not have any signiﬁcant effect on
phagocytosis capacity ofmonocytes or granulocytes (Supplementary
Fig. 5 A,B). In addition, treatment of monocytes with 1e10 mg/ml VB-
201 had no effect on monocyte adhesion to HUVEC compared to the
solvent control (Supplementary Fig. 5C). These experiments suggest
that the effect of VB-201 is process-speciﬁc, regulating monocyte
chemotaxis but not their phagocytosis or adhesive properties.
3.3. VB-201 does not affect the expression level of chemokine
receptors in monocytes
Looking into possible mechanism/s by which VB-201 reduces
monocyte chemotaxis, we ﬁrst analyzed the expression level of key
monocyte chemokine receptors. To this end, monocytes were
treated for 3.5 h with 1e5 mg/ml VB-201, conditions which are suf-
ﬁcient to inhibit monocyte migration. Subsequently, cells were
stainedwithﬂuorescently-labeledantibodies againstCXCR1, CXCR2,
CCR1, CCR2, CCR5 or CCR7 and were analyzed for receptor expres-
sion of by ﬂow cytometry. We were unable to detect any change in
the expression level of any of the tested chemokine receptors in VB-
201 treated samples relative to the solvent control (Fig. 2AeC),
suggesting that reduction of chemokine receptors is not the mech-
anism of action used by VB-201 to inhibit monocyte migration.
3.4. VB-201 is not a chemokine receptor agonist or antagonist
Next, we asked whether VB-201 regulates activation of che-
mokine receptors, either as an agonist or as an antagonist. Using
Fig. 2. VB-201 does not modulate chemokine receptors expression or activity. Human monocytes were treated with solvent or escalating doses of VB-201 for 3.5 h, after which the
expression levels of (A) CXCR1 and CXCR2, (B) CCR1 and CCR5 and (C) CCR2 and CCR7 was quantiﬁed by FACS. (D) GPCR activation assay measuring the effect of 7.35 mg/ml
(w12.5 mmol/l) VB-201 on Caþþ ﬂux in a panel of cell lines, each expressing a different chemokine receptor. (E) CCR2B antagonist assay performed in the presence of escalating
doses of VB-201, VB-207 (inactive molecule, negative control) or RS102895 (CCR2B antagonist, positive control). (F) CCR5 antagonist assay performed in the presence of escalating
doses of VB-201 or VB-207.
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expressing different chemokine receptors were treated with VB-
201 to assess receptor activation or inhibition by measurement
of Caþþ ﬂux. Treatment with VB-201 yielded less than 5% acti-
vation relative to positive controls (Fig. 2D), suggesting that it is
not an agonist of any of the tested receptors. Similarly, VB-201 did
not induce antagonistic effect on CCR2B and CCR5 receptors
expressed in ChemiScreen cell lines (Fig. 2E,F), in spite of its
ability to inhibit chemotaxis induced by ligands of these receptors
(MCP-1 and RANTES, respectively, Fig. 1B). These experiments
suggest that VB-201 is not a direct regulator of chemokine re-
ceptors activ ity.3.5. Chemokine receptor signaling in monocytes is inhibited
by VB-201
Since VB-201 had no effect on chemokine receptors expression
and direct activation, we decided to explore signaling pathways
activated downstream of chemokine receptors. For this purpose,
we pre-treated human monocytes with solvent or 5 mg/ml VB-201
and then stimulated the cells with various chemokines, including
MCP-1, MCP-3 (CCL7; ligand for CCR1, CCR2, CCR3), MIP-1a, Frac-
talkine (CX3CL1; CX3CR1 ligand) and RANTES. Following chemo-
kine stimulation, whole cell lysates were collected at different time
points and the activation state of AKT, the MEKeERK axis and p38
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ingly, VB-201 pretreatment caused profound reduction in the
phosphorylation level of AKT, MEK1/2 and ERK1/2 in MCP-1 or
MCP-3 stimulated cells. The p38 pathway was not activated underFig. 3. VB-201 inhibits chemokine-induced signaling in human monocytes. (A) Monocytes
(20 ng/ml) or MCP-3 (50 ng/ml). Untreated cells serve as a reference for chemokine stim
stimulation with MIP-1a (50 ng/ml), Fractalkine (50 ng/ml) or RANTES (50 ng/ml). Phosphor
(1 mmol/l), Rapamycin (1.1 mmol/l) and the RAF inhibitor GW5074 (1 mmol/l) decrease chemo
enhanced by VB-201 (gray bars). Data are mean  SD from 4 experiments in triplicates, nor
5 mg/ml, except for the RANTES stimulation which was performed with 2 mg/ml.these settings and was unaffected by VB-201 (Fig. 3A). VB-201-
mediated inhibition of chemokine receptor downstream signaling
was seen also for monocytes stimulatedwithMIP-1a, Fractalkine or
RANTES (Fig. 3B). Overall, VB-201-treatement either blockedwere incubated for 20 min with solvent or VB-201 prior to stimulation with MCP-1
ulation. (B) Monocytes were incubated for 20 min with solvent or VB-201 prior to
ylation of ERK1/2 was tested at different time points post stimulation. (C) Wortmannin
taxis of THP-1 cells in vitro, but their effect (at sub-maximal doses; black bars) is further
malized to untreated cells. **p < 0.001. The concentration of VB-201 in all settings was
E. Feige et al. / Atherosclerosis 229 (2013) 430e439436downstream signaling, or reduced its intensity, yielding weaker
phosphorylation in over shorter period of time.
How are these signaling ﬁndings relevant for functional
monocyte chemotaxis? To address this question, we examined the
effect of the PI3KeAKT and the RAFeMEKeERK pathways on
chemotaxis of THP-1 cells using commercially available inhibitors.
Cells were pre-incubated with solvent, the PI3K inhibitor Wort-
mannin, the mTOR inhibitor Rapamycin, or the RAF inhibitor
GW5074, alone (all at sub-maximal doses) or in combination with
VB-201, and subjected to chemotaxis assay using 2% FBS/RPMI-
1640 supplemented with MCP-1 and RANTES (100 ng/ml each) for
attraction. Treatment of THP-1 cells with VB-201 (5 mg/ml)
reduced chemotaxis byw70% relative to a solvent control (as also
shown in Supplementary Fig. 2A). Similarly, Wortmannin (1 mmol/
l), Rapamycin (1.1 mmol/l) and GW5074 (1 mmol/l) signiﬁcantly
reduced THP-1 chemotaxis, demonstrating the importance of
PI3K, mTOR and RAF for THP-1 chemotaxis. Notably, a combina-
tion of VB-201 with each of these inhibitors yielded signiﬁcantly
stronger inhibition relative to inhibitor alone or VB-201 alone
(Fig. 3C). Collectively, these data suggest that VB-201 inhibits
activation of the MEKeERK and PI3KeAKT pathways in
chemokine-stimulated monocytes, resulting in reduced chemo-
tactic capacity.
3.6. Cell speciﬁcity of VB-201
Since chemokine receptors are expressed on different immune
cells, we asked whether the effect of VB-201 is of broad ‘phos-
pholipid’ nature, or perhaps is cell-speciﬁc. At dose of 5 mg/ml of
VB-201, which dramatically inhibits monocytes chemotaxis, we
were unable to ﬁnd any inhibition of CD4þ cell chemotaxis in
multiple tested donors (Supplementary Fig. 6A). Similarly, VB-201
had no effect on chemotaxis of human neutrophils towards LPS
or RPMI-1640 medium supplemented with 10% FBS/MCP-3
(Supplementary Fig. 6B). The effect of VB-201 on cell motility
seems to be cell-speciﬁc.
3.7. VB-201 inhibits in vivo monocyte migration in the mouse
peritonitis model
To test whether VB-201 can inhibit monocyte migration in vivo,
we took advantage of the well-characterized mouse model ofFig. 4. VB-201 inhibits monocyte chemotaxis in vivo. (A) C57B6/J WT mice were orally adm
thioglycollate was injected to the peritoneal cavity of the mice to induce monocyte migrat
peritoneum and counted by hemocytometer. Data are mean  SE, collected from 3 to 4 indep
characterize their identity, migrating cells were stained with the macrophage marker F
demonstrates that w95% of the cells isolated from the peritoneum are macrophages.thioglycollate-induced peritonitis. In this model, injection of thio-
glycollate to the peritoneal cavity induces a “sterile” inﬂammatory
response recruiting peripheralmonocytes to the peritoneum,where
they differentiate intomacrophages [24]. To this end, mice were fed
with different doses of VB-201 for 5 days prior to thioglycollate in-
jection. Upon sacriﬁce, the number and identity of the cells accu-
mulating in the peritoneum was determined by FACS, and plasma
sampleswere taken for determination of VB-201 levels. As expected
for this experimentalmodel, three days after thioglycollate injection
95% of the cells in the peritoneum were macrophages (F4/80 posi-
tive, GR-1 negative cells) (Fig. 4B).
Comparing the number of accumulating macrophages in the
control animals versus VB-201-treated groups, we noticed that the
lowest dose of 0.04mg/kg/day of VB-201 had no inhibitory effect on
macrophage accumulation, as was expected with such a low dose.
However, a dose of 0.4 mg/kg, which yielded 0.8  0.3 mmol/l VB-
201 in mice plasma, resulted in w25% inhibition. Notably, when
mice were fed with 4 mg/kg VB-201, dosing which yielded plasma
level of 8.5  1.5 mmol/l VB-201 that was active in human mono-
cytes, we observed a profound (>60%) signiﬁcant reduction in the
number of peritoneal macrophages relative to the PBS-treated an-
imals (Fig. 4A). These data demonstrate a dose-dependent in vivo
effect of VB-201 on monocyte migration in a mouse peritonitis
model. Furthermore, the effective dose of VB-201 in mice plasma
correlated with the dose of VB-201 that inhibited chemotaxis of
human monocytes in vitro.3.8. VB-201 treatment inhibited atherosclerosis development in
ApoE KO mice
Atherosclerosis is an inﬂammatory disorder in which monocyte
dynamics play a key role. To test our hypothesis that VB-201 may
act to modulate inﬂammation via inhibition of monocyte traf-
ﬁcking, VB-201 was employed in the mouse ApoE KO model of
atherosclerosis. To evaluate the possible effect of VB-201 on
atherosclerosis development, VB-201 or PBS was administered by
daily oral gavage to young ApoE KO mice (9e11 weeks old) for 8
weeks after which animals were scariﬁed and lesions were
examined.
Since ApoE KO mice do not exhibit atheromatous lesions along
the aorta at this age, atherogenesis was evaluated at the aortic root.
Interestingly, quantiﬁcation of aortic sinus lesion area revealed thatinistered with escalating doses of VB-201 as indicated. After 5 days of administration,
ion. Four days later, mice were sacriﬁced and migrating cells were collected from the
endent experiments. Plasma concentrations of VB-201 are shown for each group. (B) To
4/80 and the neutrophils marker GR-1. FACS analysis from a representative animal
E. Feige et al. / Atherosclerosis 229 (2013) 430e439 437treatment with 1.5 mg/kg of VB-201 signiﬁcantly reduced plaque
formation relative to the PBS control (Fig. 5A). This effect was clear
in spite of the fact that VB-201 administration did not modify
mouse weight or metabolic parameters associated with elevated
risk for the development of atherosclerosis such as total plasma
cholesterol or triglycerides (Fig. 5BeD) and their lipoprotein FPLC
proﬁle (Supplementary Fig. 7).
Increased bone marrow and blood monocytosis is a known
feature of ApoE KO mice [25]. Looking into the possibility that VB-
201 reduces monocyte mobilization from bone-marrow to the
blood, we performedmonocyte counts in the bone-marrow, as well
as blood cell counts, in VB-201-treated mice versus controls.
However, there was no signiﬁcant effect of VB-201 on the number
of monocytes in the bone marrow or in the circulation, either in
ApoE/ mice or in thioglycollate-treated wild-type C57B6/J mice.
Similarly, VB-201 had no signiﬁcant effect on blood counts of
neutrophils, lymphocytes, eosinophils, basophils and platelets
(Supplementary Figs. 8 and 9).Fig. 5. VB-201 inhibits atherosclerosis development in ApoE knockout mice without affecti
(1.5 mg/kg) or PBS as a control from age of 9e11 weeks for 8 weeks. Aortic sinus lesion ar
tal cholesterol, (C) serum triglyceride and (D) body weight values of treated groups. Data ar
red O staining (4 lens) showing an atherosclerotic plaque in the aortic sinus of PBS-treat
represents 0.5 mm. The plaque and macrophages stains are dramatically weaker in VB-20
responding site in a section from VB-201-treated mouse.To test whether the VB-201-mediated inhibition of atheroscle-
rosis development correlated with reduced monocyte/macrophage
accumulation, aortic sinus lesion specimens were sectioned and
stained for macrophage presence using anti-CD68 antibody. As
presented in Fig. 5E, macrophage accumulation in the aortic sinus
lesion was reduced in VB-201-treated animals relative to controls.
These data indicate that treatment with VB-201 inhibited macro-
phage accumulation in atherosclerosis plaques, which correlated
with smaller lesions.
4. Discussion
Inhibition of leukocyte chemotaxis towards inﬂammatory sites
is an attractive anti-inﬂammatory approach which could be
implemented in various chronic diseases. Accordingly, pharma-
ceutical companies have put in a signiﬁcant effort in this direction,
developing inhibitors, blocking antibodies and antagonists of che-
mokine receptors, including CCR1-5, CCR9 and CXCR1-4. Datang their lipid proﬁle. (A) ApoE KO mice were treated with a daily oral dose of VB-201
ea was assessed by oil red O staining. Data are mean  SE (n ¼ 11e12/group). (B) To-
e mean  SE (n ¼ 11e12/group). NS ¼ not signiﬁcant. (E) Representative pictures of oil
ed animal, which is correlated by high macrophage content (10 lens). The scale bar
1-treated animals. Arrows point to a lesion site in a PBS-treated animal and to a cor-
E. Feige et al. / Atherosclerosis 229 (2013) 430e439438emerging from clinical trials have provided proof-of-concept to this
strategy. Nevertheless, over the recent years there have been
several phase II clinical trial failures with chemokine receptor an-
tagonists, possibly due to redundancy of the target receptor and the
complexity of heterogeneous diseases such as multiple sclerosis
and rheumatoid arthritis [26]. It has been suggested that devel-
opment of dual or promiscuous antagonists, which may simulta-
neously inhibit two or more different receptors may overcome the
redundancy hurdle [26,27].
VB-201 is rationally designed, oxidized but non-oxidative
phospholipid analog which was developed by VBL Therapeutics
along with other phospholipid pipeline molecules of the lecinoxoid
family. When tested in experimental animal models in vivo, VB-201
ameliorated the severity of experimental autoimmune encephalo-
myelitis (EAE) induced by myelin oligodendrocyte glycoprotein
(MOG) peptide MOG35e5521 and showed promising efﬁcacy in
rheumatoid arthritis and colitis models (data not shown). Yet, it
was unclear how VB-201 induces such anti-inﬂammatory effects.
Our previous work has shown that VB-201 limited inﬂammatory
cell inﬁltration into the CNS and restricted Th1 cell polarization
[21]. In this study, we report anti-atherogenic activity of VB-201
and provide mechanistic insight to VB-201-mediated inhibition of
monocyte chemotaxis in vitro and in vivo.
The MEKeERK pathway is important for monocyte chemotaxis
and its inhibition signiﬁcantly hampers monocyte migratory
properties [28,29]. The PI3KeAKT pathway was also implicated in
cell chemotaxis, and PI3K inhibitors reduced monocyte migration
in vitro [29,30]. Furthermore, knockout of PI3Kg or Akt1 reduced
monocyte/macrophage chemotaxis [31,32]. In vitro kinase assays
indicate that VB-201 does not inhibit human PI3Ks, AKT1, c-RAF,
MEK1 or ERK2 enzymatic activity (data not shown), however it
leads to blunted AKT and ERK1/2 activation upon chemokine
stimulation, in a manner which can be enhanced by combination
with inhibitors of PI3K, mTOR or RAF (Fig. 3).
Our data demonstrate that VB-201 does not block the initial
event of chemokine receptor activation but rather inhibits signaling
events downstream of the receptor in a mechanism yet to be
deﬁned. In this sense, VB-201 induces a polypharmacological effect
independent of the ligand/receptor employed. Nevertheless, the
fact that VB-201 did not alter other monocytic activities such as
phagocytosis or adhesion to activated endothelial cell and did not
inhibit granulocyte phagocytic activity (Supplementary Fig. 5) or
the chemotactic capacity of T-cells and neutrophils (Supplementary
Fig. 6), suggest that the inhibitory effect of VB-201 is process- and
cell-speciﬁc.
Two different models were employed in this study to test the
hypothesis that VB-201 may inhibit monocyte chemotaxis in vivo.
In the thioglycollate-induced mouse peritonitis model, VB-201-
treatment resulted in dose-dependent inhibition of macrophage
accumulation in the peritoneum (Fig. 4). In the second model, VB-
201 inhibited atherosclerosis development in ApoE KO mice with
clear evidence of reduced lesional macrophage staining (Fig. 5E).
The observation that VB-201 treatment reduced lesion size irre-
spective of the lipid proﬁle, further supports the contention that
the immunomodulatory properties of VB-201 are responsible for its
anti-atherogenic effects. Intriguingly, such properties may be
shared by native phospholipid species, as in vitro inhibition of
monocyte chemotaxis was also seen with the native oxidation-
product PGPC (Fig. 1). It is conceivable that the net pro- versus
anti-inﬂammatory effect of phospholipids in vivo is dependent on
the identity, abundance and half-life of the phospholipid species
found in the circulation and lesion site. By shifting the balance from
pro- to anti-inﬂammatory molecules, for example through delivery
of a stable anti-inﬂammatory lecinoxoid such as VB-201, the in-
ﬂammatory process may be restrained.Over the past few decades, prevention and treatment of
atherosclerosis have been mostly focused on regulation of choles-
terol and blood-pressure. Statins, anti-coagulation and blood-
pressure-lowering drugs have helped millions worldwide, and
multiple drugs in development continue to pursue the lipid angle
of atherosclerosis as a target. Nevertheless, numerous recent
studies have emphasized that inﬂammation plays a signiﬁcant role
in atherosclerosis, and this key vector has not been adequately met
thus far. Our ﬁndings demonstrate for the ﬁrst time in vivo inhibi-
tion of monocytes migration by an oral phospholipid-based small
molecule, which reduces macrophage accumulation and decreases
experimental atherosclerotic lesion development even without
affecting the cholesterol or triglyceride levels. Such data may pave
the way towards modulation of chronic inﬂammatory disorders via
regulation of monocyte trafﬁcking, using oral anti-inﬂammatory
synthetic phospholipid analogs.Sources of funding
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